Asthma drug roflumilast tested for Long-Term safety in new study
NCT ID NCT00246922
First seen Feb 20, 2026 · Last updated May 20, 2026 · Updated 14 times
Summary
This study looked at the long-term safety of the drug roflumilast in adults with asthma. Participants had already finished a 24-week study and took the drug once daily for another 28 weeks. The goal was to see if the drug remained safe over a longer period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
Osaka, Japan
Conditions
Explore the condition pages connected to this study.